Zhang Jun, Xu Xiaojian, Chen Zongxin, Zhu Zhengyu, Hou Jianquan
Department of Urology, Dushu Lake Hospital Affiliated to Soochow University, Suzhou, China.
Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Evid Based Complement Alternat Med. 2022 Sep 10;2022:6886590. doi: 10.1155/2022/6886590. eCollection 2022.
The aim of the study is to investigate the prognostic value of plasma interleukin-35 in the surgical treatment of patients with clear cell renal cell carcinoma (ccRCC). . Plasma IL-35 levels were measured in patients with ccRCC. The cut-off value of IL-35 was determined by the receiver operating characteristic (ROC) analysis and the area under the curve (AUC). The effects of the IL-35 and other clinicopathological characteristics on overall survival (OS) and progression-free survival (PFS) were evaluated using the univariate and multivariate logistic regression analysis.
Sixty-four ccRCC patients admitted to the urology department at the First Affiliated Hospital of Soochow University were selected, of whom 50 were diagnosed with localized ccRCC. Plasma interleukin-35 levels were significantly higher in patients with ccRCC than that in healthy controls. The cut-off value of IL-35 was 99.7 pg/mL. Multivariate analysis selected by univariate analyses demonstrated that the preoperative IL-35 was an independent prognostic factor for 5-year OS (OR: 1.02, 95% CI: 1.01 to 1.04, < 0.0001) and 5-year PFS (OR: 1.02, 95% CI: 1.00 to 1.03, =0.011) in all patients with localized ccRCC.
Current results indicate that preoperative IL-35 is an independent prognostic marker for OS and RFS in patients with localized ccRCC after surgery.
本研究旨在探讨血浆白细胞介素-35在透明细胞肾细胞癌(ccRCC)患者外科治疗中的预后价值。检测ccRCC患者的血浆白细胞介素-35水平。通过受试者工作特征(ROC)分析和曲线下面积(AUC)确定白细胞介素-35的临界值。采用单因素和多因素逻辑回归分析评估白细胞介素-35及其他临床病理特征对总生存期(OS)和无进展生存期(PFS)的影响。
选取苏州大学附属第一医院泌尿外科收治的64例ccRCC患者,其中50例被诊断为局限性ccRCC。ccRCC患者的血浆白细胞介素-35水平显著高于健康对照组。白细胞介素-35的临界值为99.7 pg/mL。单因素分析筛选出的多因素分析表明,术前白细胞介素-35是所有局限性ccRCC患者5年总生存期(OR:1.02,95%CI:1.01至1.04,<0.0001)和5年无进展生存期(OR:1.02,95%CI:1.00至1.03,=0.011)的独立预后因素。
目前的结果表明,术前白细胞介素-35是局限性ccRCC患者术后总生存期和无复发生存期的独立预后标志物。